Member Info for GLTader

I don't know why they won't just answer! I never believe in silly questions, but this is verging on it though - sorry! YGEN got onto the govt framework across all four categories. I imagine a full DD and supporting documentation have been provided / performed. The Clarigene test also received various approvals in UK and other markets.
If you go to government website for Day 2 tests (I just did as had to book one for return travel) - then Yourgene powered tests appear in quite a number of provider. I am glad actually it is in quartile 1 (cheapest) all the way to quartile 3 (more expensive)......

Errrr.......isn't it because this list is the DEVICE and not the test kit itself? The test kits should be in the 100s!! But they typically run on a handful of devices......

Interesting read:
https://www.fiercebiotech.com/medtech/jpm-2022-illumina-posts-new-sales-records-outlines-future-long-read-chemistry-plans

I certainly don't want us to put up the "for sale" sign at this stage of our business - underselling it. Wouldn't mind a hostile takeover approach though. The volumes are small and MM are moving it down at every chance given sentiments. When you look at the buys v sells since turn of year, it's been balanced yet we are lower. I think the following will reverse the trend and create momentum:

- another strong trading update with firm commitment to FY expectations and FY22/23;
- a capital restructure of some sort eg netting share premium v p/l loss reserve to enable dividend distribution in future: a sure sign of confidence;
- US market traction in the form of client names, initial sales order sizes and expectations going forward: this can easily counter Covid income and more;
- Director buys; and
- Capital markets day.

Just seen that vacancies list now 21 roles (versus 14 when I wrote earlier this week). And those in Canada are finance and ops role. Now, for those who have run businesses, you don't expand that team until you see & have growth!

Keep the faith. 2022 may indeed just be our year, finally.

A good sign of a growing business is talent acquisition - and YGEN certainly have continued to build scale across its hubs. Latest vacancy list now 14 people, with more in Canada - the entry into large NA market.

Regardless of Covid PCR test requirements, the speed at which we developed and then scaled up our offering in this space, to me, proves out the ability / credibility of YGEN. Being awarded multiple government contracts simply validates it. Molecular genetics & sequencing here to stay and only growing.

We can look forward to in Q1 calendar year:
Trading update (this month);
US launch progress;
More commercial contracts;
Capital markets day.

Last placing at 17p and we have progressed since, enough said. Good luck all.

It is a shame re SP performance. However, there is now a clear recognition of its underperformance by the directors and a concerted effort (with plans) to get a re-rating.
I reckon 2022 could be our year. Maintain Covid / genomic sequencing related business. Grow US business exponentially. Accelerate product and geographic expansion plans. Continue over-delivering on results. Start investor / capital markets day. It's then a matter of time.
Good luck all.

Based on the SP performance, you would think HY results and presentation thereof were poor. Quite the opposite.
Never mind, whoever is selling, I am buying.
2022 should be another transformational year. USA will be a key market and judging from the investments to scale up, growth will be like our Covid offering story! And once that takes off, the market will wake up.
Good luck all.

The daily share price action, and since rumours of PE interests, have been very intriguing - backed up by heavy volume. I am definitely on Compound's side in his analysis and observation.
Wouldn't be surprised we get an announcement soon of significant stake building, maybe even the likes of Elliot, who probably smell value. Quite evidently, the sum of parts is worth much more than what the current SP is! Vantage, Vodacom are listed.....
In the meantime, enjoy the yield and happy to be on the ride!

All my questions (post trading update AND during IMC) answered too, and satisfactorily. Feel more assured and have a much better understanding of the decisions being taken.
I am most encouraged with answer to one of my questions: Encouraging to see significant investments in Canada / US to enable scale - is it safe to assume this is off the back of healthy projections of sales?
Answer (something like this): Yes. When you deal with Labcorp, it is almost like signing up with Walmart. They expect supply chain to be able to cope. So, yes, we expect significant sales.
This confirms the scale of the opportunity in NA - will be key growth in FY22/23.
I also enjoyed the details on use of facilities / investments made post Covid - even if expectation is Covid will be here to stay for the next 2 years!
The recognition of the need to tell our story better and to focus on that, to aid SP, is also most encouraging.
Holding, adding and confident.
All the best.

14th December. Here's to a good detailed set of HY results and outlook.
All the best.

The Surge Contract from the National Microbiology Framework Agreement has an extension clause of 4 weeks prior to end of initial term (14/11), and thereafter 2 x 4 weeks, so about 3 months in total. Would be good to know its status. Also, how the implementation of the first US contract - activities kicking off in Q4 this year.
I will be surprised if we don't hit £30m for FY22 with and an EBITDA of £4m. With any luck, we may just tip into the black on reported OP. Looking forward to update in the days to come.
We have been quiet for 4 months on commercial front so must be due something!
Good luck all.

Perhaps this might help.

https://moneyweek.com/investments/stockmarkets/uk-stockmarkets/604168/two-outstandingly-cheap-uk-stocks-in-an-age-of-mad

Bakky, I think it is more than important enough to RNS. Can our test delineate the Omicron variant? Has our govt contract been extended? This is what I mean by YGEN being VERY poor at PR. They really don't help themselves, ie us! I rarely rant but if there is a general feeling SP is below value of company, RNS like this will help!

Very good. We need to get Omicron under control.
I JUST WISH YGEN WILL SAY SOMETHING! THE SILENCE IS DEAFENING.
I know we have our core business et al, but Covid / genetic sequencing business is also becoming mainstream for us.

I recall there is an extension clause - yep, come on YGEN, tell us how the business is doing!

Awful re new variant. Hopefully YGEN can do its part though, today and into the future.

Well, one thing for sure. Covid is here to stay, however we live with it. Just heard several schools sending kids home and families needing PCR tests. So, our surge contract must be busy, and will be good to hear its extension.

I see we have another new senior hire: APAC Senior Director of Business Development, Dr Aarti Gokhale. Looks like we are now pushing on the commercial / growth front and with our broadened portfolio should be timely.

For those who haven't, I would also recommend reading the Annual Report for FY2021 - the glossy as I call these. Some good information in there, especially also the Q&A with Scott Sargeant. US will be a big market for us, hopefully. APAC back to growth too. UK and Europe already strong.

Gosh, twix386, you single-handedly contribute 80% of posts in this BB. The "attacks", rightly or wrongly, are because you effectively tell us your daily activities, predictions and rants - really, everyone, please let's focus on informative posts and debates on YGEN. Anyone coming on this BB will be turned off!

Let me start. I wrote to the company recently after interims, and received a reply via Walbrook PR. Nothing not already announced but I remain confident the management are trying to build a global business, diversifying across an increasing portfolio of product and services that will better provide for a sustainable revenue growth (Covid and non-Covid related) and reversing the lost credibility in missed projections in FY20/21.

I am looking forward to a lot more details in the interim results across FY and after expectations, investments made and why, our growth roadmap across core and Covid related products / services etc. I also anticipate cash levels to be closer to £10m by year end - what's the plan? With any luck, we may hear about US contracts (they continue to expand in Canada) and UK govt tenders before then.

Staying optimistic. All the best.

Net debt will fall once the convertible bonds gets converted, which is the buybacks have been funding. So a timing thing, I think. Very solid results and suspect rumours of takeover will come again.